Vertex Pharmaceuticals announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $315 from $312 at Canaccord
- Vertex: VX-548 preclinical studies, Phase 2, proof-of-concept results published
- Vertex Pharmaceuticals price target raised to $425 from $410 at Wells Fargo
- Vertex Pharmaceuticals price target raised to $370 from $360 at TD Cowen
- Vertex Pharmaceuticals price target raised to $390 from $380 at Bernstein
Questions or Comments about the article? Write to editor@tipranks.com